| Literature DB >> 32828699 |
Nanze Yu1, Zhijin Li1, Xiao Long1, Jiuzuo Huang1, Wei Cao2, Yan Zhang3, Yang Yang4, Zhengyin Liu2, Zhifei Liu1, Shuyang Zhang5, Xiaojun Wang6.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32828699 PMCID: PMC7424384 DOI: 10.1016/j.bjps.2020.08.006
Source DB: PubMed Journal: J Plast Reconstr Aesthet Surg ISSN: 1748-6815 Impact factor: 2.740
Characteristics of 46 Critical Covid-19 Patients with Pressure Injury.
| Characteristic | Total ( | Stage I ( | Stage II ( | Stage III–IV /Unstageable ( |
|---|---|---|---|---|
| Median age (IQR) — yr | 66(60–70) | 68(63–72) | 65(57–68) | 69(66–70) |
| Male sex — no. (%) | 27(58.7) | 5(71.4) | 18(54.5) | 4(66.7) |
| Female sex — no. (%) | 19(41.3) | 2(28.6) | 15(45.5) | 2(33.3) |
| Median interval from onset to intubation (IQR) — days | 18(12–24) | 17(13–24) | 18(13–21) | 20(14–23) |
| Fever | 40(87.0) | 5(71.4) | 29(87.9) | 6(100.0) |
| Shortness of breath | 38(82.6) | 4(57.1) | 29(87.9) | 5(83.3) |
| Cough | 36(78.3) | 5(71.4) | 26(78.8) | 5(83.3) |
| Fatigue | 20(43.5) | 5(71.4) | 12(36.4) | 3(50.0) |
| Diarrhea | 10(21.7) | 1(14.3) | 8(24.2) | 1(16.7) |
| Sputum production | 10(21.7) | 1(14.3) | 8(24.2) | 1(16.7) |
| Headache | 8(17.4) | 2(28.6) | 5(15.2) | 1(16.7) |
| Nausea or vomiting | 7(15.2) | 2(28.6) | 4(12.1) | 1(16.7) |
| Myalgia | 6(13.0) | 1(14.3) | 4(12.1) | 1(16.7) |
| Palpitation | 4(8.7) | 0 | 4(12.1) | 0 |
| Median interval from intubation to pressure injury event (IQR) — days | 9(6–12) | 9(7–12) | 9(6–12) | 7(6–10) |
| Location — no. (%) | ||||
| Sacrum | 41(89.1) | 6(85.7) | 29(87.9) | 6(100.0) |
| Face | 11(23.9) | 1(14.3) | 8(24.2) | 2(33.3) |
| Heel | 10(21.7) | 0 | 6(18.2) | 4(66.7) |
| Hip | 4(8.7) | 0 | 3(9.1) | 1(16.7) |
| Elbow | 3(6.5) | 1(14.3) | 2(6.1) | 0 |
| Scapula | 2(4.3) | 0 | 1(3.0) | 1(16.7) |
| Median size (IQR) — cm2 | 47(22–88) | 45(23–49) | 46(21–68) | 106(67–591) |
| Vasopressor support — no. (%) | 35(76.1) | 3(42.9) | 26(78.8) | 6(100.0) |
| Coexisting acro-ischemia — no. (%) | 16(34.8) | 1(14.3) | 10(30.3) | 5(83.3) |
| Intermittent haemodialysis —no. (%) | 11(23.9) | 0 | 9(27.3) | 2(33.3) |
| Wound swab sampling — no. (%) | 23(50.0) | NA | 17(51.5) | 5(83.3) |
| Hypertension | 26(56.5) | 6(85.7) | 15(45.5) | 5(83.3) |
| Diabetes | 8(17.4) | 2(28.6) | 4(12.1) | 2(33.3) |
| Cerebrovascular disease | 7(15.2) | 1(14.3) | 4(12.1) | 2(33.3) |
| Coronary heart disease | 7(15.2) | 0 | 6(18.2) | 1(16.7) |
| Cancer | 5(10.9) | 0 | 5(15.2) | 0 |
| Chronic obstructive pulmonary disease | 4(8.7) | 1(14.3) | 2(6.1) | 1(16.7) |
| Chronic renal disease | 2(4.3) | 1(14.3) | 0 | 1(16.7) |
| White-cell count (per mm3) | 10,940(6400–15,380) | 13,360(6510–17,120) | 10,830(8710–14,350) | 12,070(5970–21,840) |
| Differential count (per mm3) | ||||
| Total neutrophils | 9820(6270–13,660) | 12,490(5540–15,650) | 9690(7750–12,550) | 9930(5600–19,920) |
| Total lymphocytes | 550(410–780) | 660(470–820) | 560(440–750) | 370(180–630) |
| Total monocytes | 420(280–570) | 370(270–780) | 430(310–550) | 330(140–480) |
| Hemoglobin (g/l) | 81(69–92) | 92(87–96) | 78(68–90) | 80(76–85) |
| Platelet count (per mm3) | 181,000(118,300–243,500) | 248,000(205,500–290,500) | 180,000(119,000–230,000) | 73,000(37,000–205,800) |
| Albumin (g/l) | 23.9(21.5–26.0) | 25.2(24.2–36.5) | 23.0(21.2–24.8) | 25.3(24.0–27.9) |
| Creatinine (µmol/l) | 103(67–127) | 96(62–126) | 93(60–121) | 124(114–133) |
| Prothrombin time (s) | 16.2(15.0–17.4) | 15.3(15.2–16.5) | 16.2(14.9–17.7) | 16.8(15.1–17.1) |
| Activated partial-thromboplastin time (s) | 43.5(41.5–47.7) | 44.7(39.5–46.0) | 43.0(40.8–48.3) | 45.9(44.2–47.6) |
| Fibrinogen (g/l) | 4.3(3.2–5.9) | 5.9(5.0–8.4) | 4.3(3.1–5.8) | 3.7(2.4–4.0) |
| Fibrin degradation products (mg/l) | 53.0(18.9–150.0) | 14.2(6.0–19.6) | 71.8(27.6–150.0) | 94.5(37.3–150.0) |
| D-dimer (mg/l) | 21(5.5–21.0) | 3.9(2.3–4.9) | 21.0(13.2–21.0) | 11.1(5.2–18.9) |
| High-sensitivity C-reactive protein (mg/l) | 75.6(43.4–140.2) | 54.6(21.9–65.9) | 99.9(47.0–161.4) | 54.7(41.3–109.4) |
| Discharged from ICU — no. (%) | 16(34.8) | 3(42.9) | 10(30.3) | 3(50.0) |
| Died in ICU — no. (%) | 30(65.2) | 4(57.1) | 23(69.7) | 3(50.0) |
Stage I pressure injury describes intact skin with non-blanchable erythema. No swab sample was obtained in this stage.
Any type of cancer was included in this category.
All the laboratory values were obtained from laboratory reports before medical intervention.
The reference value for the fibrin degradation products level was 150 mg/l or less.
The reference value for the D-dimer level was 21 mg/l or less.